How to access Ctexli for cerebrotendinous xanthomatosis from the UAE: 2026 pathway via SSMC, CCAD, and Tawam metabolic-genetics programmes | Reserve Meds

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

The UAE diagnoses CTX through paediatric and adult neurology referrals at Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi (CCAD), and Tawam Hospital, with additional cases captured at Burjeel Medical City and Mediclinic City Hospital Dubai. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement therapy for CTX, given that EDE has not yet domestically registered the product.

Why Ctexli, why now

Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts bile-acid synthesis and leads to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and cognitive decline. Most patients develop neurologic symptoms in the second or third decade if untreated.

The 2026 question for a UAE patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with the Emirates Drug Establishment (EDE), so the UAE pathway is named-patient personal-import authorisation under EDE's personal-medication framework.

What Ctexli is, in plain language

Ctexli is an oral chenodiol capsule. Mechanistically it replaces the bile acid (chenodeoxycholic acid) the patient's deficient enzyme cannot produce and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, lowering accumulated cholestanol. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.

Access pathway in the UAE

The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance for the UAE. The Department of Health Abu Dhabi (DoH Abu Dhabi), the Dubai Health Authority (DHA), and MOHAP for the Northern Emirates govern healthcare facility licensing. Ctexli is not currently EDE-registered. Access runs through an EDE-approved named-patient personal-import authorisation, with the relevant emirate-level health authority acknowledgment, filed by the treating clinician at SSMC, CCAD, Tawam, SKMC, Burjeel Medical City, Mediclinic City Hospital Dubai, American Hospital Dubai, or one of the other licensed specialty centres. The UAE diagnoses CTX through paediatric and adult neurology referrals at Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi (CCAD), and Tawam Hospital, with additional cases captured at Burjeel Medical City and Mediclinic City Hospital Dubai.

The treating neurologist or metabolic specialist submits the named-patient import application documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Abu Dhabi or Dubai International Airport.

Eligibility at a UAE metabolic-genetics or neurology clinic

Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). The CCAD genetic disease programme, SSMC metabolic clinic, and Tawam paediatric neurology each handle confirmation. Paediatric cases are managed in paediatric neurology at SSMC, CCAD, Tawam, or via cross-border referral to Sidra Medicine Qatar; adult cases run through adult neurology at SSMC, CCAD, SKMC, or the Dubai-based centres. The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features).

Documentation required

The patient and physician should be prepared to provide: a current Emirates ID or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the EDE named-patient import application; the emirate-level health authority acknowledgment (DoH Abu Dhabi, DHA, or MOHAP); and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.

Costs and funding considerations

The annual cost band for Ctexli in the UAE is USD 150,000 to 220,000 per patient (AED 550,000 to 810,000), weight-dependent, lifelong. Pre-approval, CTX patients in the region were typically maintained on compounded chenodeoxycholic acid at substantially lower cost; FDA-approved Ctexli carries a manufacturer premium. Thiqa coverage for Emirati nationals may apply under the rare-disease provision case-by-case. DHA Saada for Emirati nationals in Dubai applies similarly. Daman Enhanced, AXA Gulf, Allianz, MetLife, and BUPA Arabia plans typically require pre-authorisation with the genetics report and a treating-specialist letter; coverage for an unregistered ultra-orphan agent is unusual but not impossible. Reserve Meds will help structure the insurer or government-payor submission.

Typical timeline

Weeks 0 to 4: confirm diagnosis, prescription preparation, EDE import filing through the UAE hospital pharmacy. Weeks 4 to 8: shipment arrival at Abu Dhabi or Dubai International Airport, initiation under metabolic-clinic supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, and tolerability monitoring. Months 6 and 12: full metabolic and neurologic reassessment, repeat plasma cholestanol, and brain MRI white-matter assessment.

When Ctexli is the wrong drug

Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment.

Frequently asked questions

• Is the pathway legal in the UAE? Yes. It operates under EDE named-patient personal-import authorisation with emirate-level health authority acknowledgment under federal UAE medicines law.
• Will Thiqa, DHA Saada, or my insurance cover Ctexli? Emirati nationals may secure Thiqa or DHA Saada rare-disease case-by-case support; private insurance coverage for ultra-orphan agents is unusual but pre-authorisation with documented genetics is the path to attempt.
• How long does treatment continue? Lifelong. CTX is a chronic genetic disease.
• Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
• What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
• Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in the UAE are typically managed at SSMC, CCAD, Tawam paediatric neurology, or via cross-border Sidra confirmation.

Closing

Reserve Meds runs the Ctexli supply file from the SSMC, CCAD, or Tawam metabolic-genetics referral through EDE named-patient authorisation, US or EU sourcing, and delivered supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.

Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds) with AI-assisted pharmacist and regulatory-counsel review.